Scinovex
article Open AccessTop 1% cited

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

Lara D. Veeken · 2010 · Vol. 50(1) · pp. 124–131
James GallowayKimme L HyrichLouise MercerWilliam G DixonBo FuAndrew UstianowskiKath WatsonMark LuntDeborah Symmonson behalf of the British Society for Rheumatology Biologics Register

Abstract

These data add to currently available evidence suggesting that anti-TNF therapy is associated with a small but significant overall risk of SI. This must be balanced against the risks associated with poor disease control or alternative treatments.

Rheumatoid Arthritis Research and TherapiesAutoimmune and Inflammatory Disorders ResearchSystemic Lupus Erythematosus ResearchMedicineEtanerceptAdalimumabInfliximabInternal medicineRheumatoid arthritisHazard ratioRheumatologyCohortOdds ratio

MeSH terms

Tumor Necrosis Factor InhibitorsAgedAntibodies, MonoclonalArthritis, RheumatoidFemaleUnited KingdomHumansInfectionsMaleMiddle AgedRegistriesRegression AnalysisRisk FactorsAntirheumatic AgentsTumor Necrosis Factors
Citations
665
FWCI
31.04
field-weighted impact
References
34
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly · Scinovex